Literature DB >> 28195237

Head and neck cancer: Buparlisib is an effective second-line treatment.

Peter Sidaway.   

Abstract

Entities:  

Year:  2017        PMID： 28195237     DOI： 10.1038/nrclinonc.2017.22

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

Authors:  Denis Soulières; Sandrine Faivre; Ricard Mesía; Éva Remenár; Shau-Hsuan Li; Andrey Karpenko; Arunee Dechaphunkul; Sebastian Ochsenreither; Laura Anna Kiss; Jin-Ching Lin; Raj Nagarkar; László Tamás; Sung-Bae Kim; Jozsef Erfán; Anna Alyasova; Stefan Kasper; Carlo Barone; Sabine Turri; Arunava Chakravartty; Marie Chol; Paola Aimone; Samit Hirawat; Lisa Licitra
Journal:  Lancet Oncol       Date:  2017-01-26       Impact factor: 41.316
  1 in total
  1 in total

1.  MicroRNA-103a-3p Promotes Cell Proliferation and Invasion in Non-Small-Cell Lung Cancer Cells through Akt Pathway by Targeting PTEN.

Authors:  Haixun Li; Muren Huhe; Jiaxin Lou
Journal:  Biomed Res Int       Date:  2021-07-07       Impact factor: 3.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.